Full Breakdown
Judge Blocks Trump Halt on Hormone Therapy for Transgender Prisoners
6/19/2026, 1:41:53 AM
Core Legal Decision: Injunction to Continue Hormone Medications
On June 17, 2026, Judge Royce C. Lamberth of the U.S. District Court for the District of Columbia issued a preliminary injunction requiring the Federal Bureau of Prisons to continue providing hormone medications to transgender inmates. He found the government’s doubts about hormone therapy unlikely to meet the legal standard for a reasoned reversal of policy.
Background: Transgender Policy Shifts Under the Trump Administration
Since taking office, the Trump administration has enacted policies targeting transgender Americans, including mandating birth-sex designations on passports, barring transgender military service, limiting bathroom access, urging hospitals to halt gender-affirming care for youths, and redirecting federal grants from affirming organizations. In prisons, the Bureau of Prisons issued an early-2026 policy favoring psychotherapy and antidepressants instead of hormone therapy for inmates with gender dysphoria.
Key Actors: Judge, Prison System, and Advocacy Counsel
Key participants are Judge Royce C. Lamberth, who issued the injunction; the Federal Bureau of Prisons, which questions hormone therapy benefits; lawyers for transgender inmates, who cite major medical organizations supporting hormone treatment; and the federal health department, which has voiced concerns about hormone use for minors.
Timeline of Relevant Actions
- Early 2026 – Bureau of Prisons releases policy favoring psychotherapy and antidepressants over hormone therapy for transgender inmates.
- June 17, 2026 – Judge Lamberth issues preliminary injunction requiring continuation of hormone medications.
Official Statements & Responses
The Bureau of Prisons argued that hormone therapy’s benefits for adult inmates are uncertain and that psychotherapy and antidepressants should be prioritized. Inmates’ lawyers countered that transition-related care, including hormone therapy, is the only approach endorsed by major medical and mental-health organizations for gender dysphoria. The judge noted the agency’s lack of a reasoned justification for ending the treatment.
Criticism & Opposition
Critics of the administration’s transgender policies view the injunction as a setback to efforts to limit gender-affirming care. The Bureau’s opposition to hormone therapy for prisoners rests on questions about clinical efficacy and aligns with the federal health department’s caution about hormone use for minors.
Conflicting Reports & Gaps
The Bureau of Prisons calls hormone therapy’s benefits “unclear,” while prisoner advocates cite consensus among major medical bodies that the treatment is effective for adults with gender dysphoria. No quantitative data on health outcomes for transgender inmates under either approach are provided, leaving a gap in empirical evidence.
Why It Matters
The injunction establishes a judicial check on the federal government’s ability to alter medical standards for incarcerated individuals without a reasoned explanation. It also underscores the intersection of correctional health policy with broader debates over transgender rights and access to gender-affirming care.